MULTIPLE MYELOMA (MM)
Clinical trials for MULTIPLE MYELOMA (MM) explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA (MM) trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA (MM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection shows promise for tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or not responded to standard therapy. The main goals are to check safety and find the right dose. About 40 adults aged 18-75 will take part…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 17, 2026 03:00 UTC
-
New hope for myeloma patients with failing kidneys: drug combo shows promise
Disease control Recruiting nowThis study tests a combination of two drugs (CM336 and isatuximab) in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function and control the cancer. Participants receive three cycles …
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 02:59 UTC
-
New hope for multiple myeloma patients: experimental drug combo aims to slow cancer progression
Disease control Recruiting nowThis study tests whether adding an experimental drug called SCTC21C to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. About 292 participants will be…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
New hope for frail myeloma patients: shorter drug combos show promise
Disease control Recruiting nowThis study tests two new drug combinations (teclistamab plus daratumumab or talquetamab plus daratumumab) given for a fixed time in 150 frail patients newly diagnosed with multiple myeloma. The goal is to see how long the cancer stays under control and how well patients tolerate …
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE2 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo tackles tough myeloma: early trial seeks safer doses
Disease control Recruiting nowThis early-stage study is testing a new two-drug combination (cemsidomide plus elranatamab) in about 60 people whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to find a safe dose and see if the combination can shrink the cancer. Par…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Could a drug combo replace transplant for myeloma? new trial aims to find out
Disease control Recruiting nowThis study compares two approaches for people newly diagnosed with multiple myeloma: a drug combination (elranatamab and daratumumab) versus a stem cell transplant followed by maintenance drugs. The goal is to see which method better eliminates cancer cells deep in the bone marro…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: PHASE2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Exercise program aims to boost quality of life in multiple myeloma patients
Symptom relief Recruiting nowThis study tests whether a 6-month personalized exercise program, combining home and hospital sessions, can improve quality of life for people with multiple myeloma. About 86 patients aged 60 and older who are not eligible for transplant will be randomly assigned to either receiv…
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: NA • Sponsor: Centre Hospitalier Metropole Savoie • Aim: Symptom relief
Last updated May 11, 2026 20:52 UTC
-
New study aims to predict who will develop multiple myeloma
Knowledge-focused Recruiting nowThis observational study is looking for biological markers that can predict if early blood disorders (MGUS or SMM) will progress to multiple myeloma, a type of blood cancer. Researchers will analyze genetics, immune cells, and mouth bacteria from 60 patients and compare them to h…
Matched conditions: MULTIPLE MYELOMA (MM)
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated May 17, 2026 03:09 UTC
-
Scientists hunt for clues to make CAR-T last longer in myeloma
Knowledge-focused Recruiting nowThis study looks at 60 adults with multiple myeloma who are about to receive CAR-T cell therapy. Researchers will measure a specific immune marker (TCF-1) in patients' blood before treatment and track how long the modified CAR-T cells persist afterward. The goal is to find early …
Matched conditions: MULTIPLE MYELOMA (MM)
Phase: NA • Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC